Skip to Content

Avadel Pharmaceuticals PLC AVDL

Morningstar Rating
$16.44 +0.32 (1.99%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AVDL is trading at a 342% premium.
Price
$16.41
Fair Value
$71.84
Uncertainty
Extreme
1-Star Price
$69.24
5-Star Price
$3.15
Economic Moat
Qzcc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVDL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$16.12
Day Range
$16.1216.60
52-Week Range
$9.5019.09
Bid/Ask
$15.05 / $17.00
Market Cap
$1.58 Bil
Volume/Avg
1 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
25.98
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
154

Valuation

Metric
AVDL
Price/Earnings (Normalized)
Price/Book Value
20.16
Price/Sales
25.98
Price/Cash Flow
Price/Earnings
AVDL

Financial Strength

Metric
AVDL
Quick Ratio
2.36
Current Ratio
2.85
Interest Coverage
−15.99
Quick Ratio
AVDL

Profitability

Metric
AVDL
Return on Assets (Normalized)
−73.01%
Return on Equity (Normalized)
−168.09%
Return on Invested Capital (Normalized)
−109.62%
Return on Assets
AVDL
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
YztldhwztSqc$81.1 Bil
Merck KGaA ADR
MKKGY
HghqhtqmnyNmsrs$72.2 Bil
Haleon PLC ADR
HLN
GjmrykvRpchc$39.4 Bil
Teva Pharmaceutical Industries Ltd ADR
TEVA
TppmkpmswRjk$19.2 Bil
Viatris Inc
VTRS
KkscrzrxbDjywc$13.3 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
BqndqrrBhsp$13.2 Bil
Catalent Inc
CTLT
CyhlqfsvSmvcmm$10.5 Bil
Perrigo Co PLC
PRGO
FygztjnxwDlh$3.8 Bil
Prestige Consumer Healthcare Inc
PBH
BpsxxsgrkWjkjyvb$3.5 Bil
Curaleaf Holdings Inc
CURLF
BgxnvbbhLrxb$3.1 Bil

Sponsor Center